Publikationslista

Minst två av författarna är SOIBD medlemmar.

2017

  1. Ludvigsson JF, Büsch K, Olén O, Askling J, Smedby KE, Ekbom A, Lindberg E, Neovius M. Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study. BMC Gastroenterol. 2017 Jan 31;17(1):23.
  2. Halfvarson J, Brislaw CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, D’Amato M, Bonfiglio F, McDonald D, Gonzalez A, McClure EE, Dunklebarger MF, Knight R, Jansson JK. Dynamics of the human gut microbiome in Inflammatory Bowel Disease. Nat Microbiol. 2017 Feb 13;2:17004.
  3. Angelison L, Almer S, Eriksson A, Karling P, Fagerberg U, Halfvarson J, Marsal J, Thörn M, Björk J, Hindorf U, Löfberg R, Bajork A, Hjortswang H, Hammarlund P, Grip O, Torp J, Hertervig E. Long-term outcome of infliximab treatment in chronic active ulcerative colitis: A Swedish multicentre study of 250 patients. Aliment Pharmacol Ther. 2017 Feb;45(4):519-532.
  4. L. Jakobsson G, Sternegård E, Olén O, Myrelid P, Ljung R, Strid H, Halfvarson J, F. Ludvigsson J. Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG). Scand J Gastroenterol. 2017 Feb;52(2):216-221.
  5. Klingberg K, Strid H, Stahl A, Deminger A, Carlsten H, Öhman L, Forsblad-d’Elia HA longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther. 2017 Feb 2;19(1):21
  6. Olén O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, Ekbom A, Malmborg P, Ludvigsson JF. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ. 2017 Sep 20;358:j3951.
  7. Amcoff K, Stridsberg M, Lampinen M, Magnuson A, Carlson M, Halfvarson J. Clinical implications of assay specific differences in f-Calprotectin when monitoring inflammatory bowel disease activity over time. Scand J Gastroenterol. 2017 Mar;52(3):344-350.
  8. Westerlind H, Mellander MR, Bresso F, Munch A, Assadi G, Hübenthal M, Lieb W, Källberg H, Brynedal B, Padyukov L, Halfvarson J, Törkvist L, Andreasson A, Agreus L, Almer S, Miehlke S, Madisch A, Ohlsson B, Löfberg R, Hultcranz R, Franke A, D’Amato M. Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis. Gut. 2017 Mar;66 (3):421-428
  9. BergemalmD, Kruse R, Sapnara M, Halfvarson J, Hultgren Hörnquist E. Elevated fecal peptidase D at onset of colitis in Gαi2 -/- mice, a mouse model of IBD. PLoSOne 2017 Mar 21;12(3):e0174275.
  10. Angelison L, Marsal J, Hertervig E. Letter: how to define remission in ulcerative colitis – histological remission should be considered. Authors’ reply. Aliment Pharmacol Ther. 2017 Apr;45(8):1177-1178.
  11. Konya V, Czarnewski P, Forkel M, Rao A, Kokkinou E, Villablanca EJ, Almer S, Lindforss U, Friberg D, Höög C, Bergman P, Mjösberg J. Vitamin D downregulates the IL-23 receptor pathway in human mucosal group 3 innate lymphoid cells. J Allergy Clin Immunol. 2018 Jan;141(1):279-292. Epub 2017 Apr 20.
  12. Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, Carneiro A, Marsal J. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017 May;66(5):581-592
  13. Nyberg L, Björk J, Björkdahl P, Ekberg O, Sjöberg K, Vigren L. Sclerosing mesenteritis and mesenteric panniculitis – clinical experience and radiological features. BMC Gastroenterol. 2017 Jun 13;17(1):75.
  14. Magnusson MK, Strid H, Isaksson S, Simrén M and Öhman L. The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis. Inflamm Bowel Dis. 2017 Jun;23(6):956-966
  15. Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, Karling P, Söderman C, The SWIBREG Vedolizumab Study Group, Myrelid P, Cao Y, Sjöberg D, Thörn M, Karlén P, Hertervig, E, Strid H, Ludvigsson JF, Almer S, Halfvarson J. Long-term effectiveness of vedolizumab in inflammatory bowel disease: A national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) Scand J Gastroenterol. 2017 Jun – Jul;52(6-7):722-729
  16. Huang H, Fang M, Jostins L, Umićević Mirkov M, Boucher G, Anderson C A, Andersen V, Cleynen I, Cortes A, Crins F, D’Amato M, Deffontaine V, Dimitrieva J, Docampo E, Elansary M, Kai-How Farh K, Franke A, Gori A-S, Goyette P, Halfvarson J, Haritunians T, Knight J, Lawrence IC, Lees CW, Louis E, Mariman R, Meuwissen T, Mni M, Momozawa Y, Parkes M, Spain SL, Théâtre E, Trynka G, Satsangi J, van Sommeren S, Vermeire S, Xavier RJ, International IBD Genetics Consortium, Weersma RK, Duerr RH, Mathew CG, Rioux JD, McGovern D PB, Cho JH, Georges M, Daly MJ, Barrett JC. Association mapping of inflammatory bowel disease loci to single variant resolution. Nature. 2017 Jul 13;547(7662):173-178.
  17. Eberhardson M, Söderling JK, Neovius M, Cars T, Myrelid P, Ludvigsson JF, Askling J, Ekbom A, Olén O. Anti-TNF treatment in Crohn’s disease and risk of bowel resection-a population based cohort study. Aliment Pharmacol Ther. 2017 Sep;46(6):589-598.
  18. Burisch, J, Vegh Z, Katsanos K, Christodoulou D, Lazar D, Goldis A, O’Morain C, Fernandez A, Pereira S, Myers S, Sebastian S, Pedersen N, Olsen J, Nielsen K R, Schwartz D, Odes S, Almer S, Halfvarson J, Turk N, Cukovic-Cavka S, Nikulina I, Belousova E, Duricova D, Shonová O, Salupere R, Barros L, Magro F, Jonaitis L, Kupcinskas L, Turcan S, Kaimakliotis I, Ladefoged K, Kudsk K, Andersen V, Vind I, Thorsgaard N, Oksanen P, Collin P, Dal Piaz G, Santini A, Niewiadomski O, Bell S, Moum B, Arebi N, Kjeldsen J, Carlsen K, Langholz E, Lakatos P L, Munkholm P, Gerdes LU, Dahlerup, J F for the EpiCom study group.Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort – An ECCO-EpiCom study J Crohns Colitis. 2017 Oct 1;11(10):1213-1222
  19. Günaltay S, Repsilber D, Helenius G, Nyhlin N, Bohr J, Hultgren O, Hultgren Hörnquist E. Oligoclonal T-cell Receptor Repertoire in Colonic Biopsies of Patients with Microscopic Colitis and Ulcerative Colitis. Inflamm Bowel Dis. 2017
  20. Wickbom A, Nyhlin N, Montgomery SM, Bohr J, Tysk C Family history, comorbidity, smoking and other risk factors in microscopic colitis: a case-control study.. Eur J Gastroenterol Hepatol. 2017
  21. Günaltay S, Rademacher L, Hultgren Hörnquist E, Bohr J. Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis. World J Gastroenterol. 2017

2016

  1. Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., and Marsal, J. Vedolizumab treatment for immune checkpoint inhibitor induced enterocolitis. Cancer Immunol. Immunother. [Springer] (Accepted)
  2. Marsal J, Hertervig E. Introduktion av biosimilarer kräver noggrann övervakning. Lakartidningen. 2016 Mar 3;113.
  3. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: A randomised, placebo-controlled 12-month trial. Münch A, Bohr J, Benoni C, Miehlke S,  Olesen M, Öst A, Strandberg L, Hellström PM, Hertervig E, Armerding P, Stehlik J, Lindberg G, Björk J, Lapidus A, Löfberg R, Bonderup O, Avnström S, Rössle M, Dilger K, Mueller R, Greinwald R, Tysk C, Ström M. Gut 2016;65:47–56.
  4. A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition. Li D, Achkar JP, Haritunians T, Jacobs JP, Hui KY, D’Amato M, Brand S, Radford-Smith G, Halfvarson J, Niess JH, Kugathasan S, Büning C, Schumm LP, Klei L, Ananthakrishnan A, Aumais G, Baidoo L, Dubinsky M, Fiocchi C, Glas J, Milgrom R, Proctor DD, Regueiro M, Simms LA, Stempak JM, Targan SR, Törkvist L, Sharma Y, Devlin B, Borneman J, Hakonarson H, Xavier RJ, Daly M, Brant SR, Rioux JD, Silverberg MS, Cho JH, Braun J, McGovern DP, Duerr RH. Gastroenterology. 2016 Oct;151(4):724-32
  5. Rivas MA, Graham D, Sulem P, Stevens C, Desch AN, Goyette P, Gudbjartsson D, Jonsdottir I, Thorsteinsdottir U, Degenhardt F, Mucha S, Kurki MI, Li D, D’Amato M, Annese V, Vermeire S, We- ersma RK, Halfvarson J, Paavola-Sakki P, Lappalainen M, Lek M, Cummings B, Tukiainen T, Hari- tunians T, Halme L, Koskinen LL, Ananthakrishnan AN, Luo Y, Heap GA, Visschedijk MC; UK IBD Genetics Consortium; NIDDK IBD Genetics Consortium, MacArthur DG, Neale BM, Ahmad T, Ander- son CA, Brant SR, Duerr RH, Silverberg MS, Cho JH, Palotie A, Saavalainen P, Kontula K, Färkkilä M, McGovern DP, Franke A, Stefansson K, Rioux JD, Xavier RJ, Daly MJ, Barrett J, de Lane K, Ed- wards C, Hart A, Hawkey C, Jostins L, Kennedy N, Lamb C, Lee J, Lees C, Mansfield J, Mathew C, Mowatt C, Newman B, Nimmo E, Parkes M, Pollard M, Prescott N, Randall J, Rice D, Satsangi J, Simmons A, Tremelling M, Uhlig H, Wilson D, Abraham C, Achkar JP, Bitton A, Boucher G, Croitoru K, Fleshner P, Glas J, Kugathasan S, Limbergen JV, Milgrom R, Proctor D, Regueiro M, Schumm PL, Sharma Y, Stempak JM, Targan SR, Wang MH. A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. Nat Commun. 2016 Aug 9;7:12342
  6. LACC1 polymorphisms in inflammatory bowel disease and juvenile idiopathic arthritis. Assadi G, Saleh R, Hadizadeh F, Vesterlund L, Bonfiglio F, Halfvarson J, Törkvist L, Eriksson AS, Harris HE, Sundberg E, D’Amato M. Genes Immun. 2016 Jun;17(4):261-4.
  7. Assadi G, Vesterlund L, Bonfiglio F, Mazzurana L, Cordeddu L, Schepis D, Mjösberg J, Sabrina Ruhrmann; Alessia Fabbri; Vladana Vukojevic; Piergiorgio Percipalle; Florian Albert Salomons; Jurga Laurencikiene; Leif Törkvist; Jonas Halfvarson; Mauro D’Amato. Functional analyses of the Crohn’s disease risk gene LACC1″. PLoS One. 2016 Dec 13;11(12):e0168276
  8. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, Park YR, Raychaudhuri S, Pouget JG, Hübenthal M, Folseraas T, Wang Y, Esko T, Metspalu A, Westra HJ, Franke L, Pers TH, Weersma RK, Collij V, D’Amato M, Halfvarson J, Jensen AB, Lieb W, Degenhardt F, Forstner AJ, Hofmann A; International IBD Genetics Consortium (IIBDGC); International Genetics of Ankylosing Spondylitis Consortium (IGAS); International PSC Study Group (IPSCSG); Genetic Analysis of Psoriasis Consortium (GAPC); Psoriasis Association Genetics Extension (PAGE), Schreiber S, Mrowietz U, Juran BD, Lazaridis KN, Brunak S, Dale AM, Trembath RC, Weidinger S, Weichenthal M, Ellinghaus E, Elder JT, Barker JN, Andreassen OA, McGovern DP, Karlsen TH, Barrett JC, Parkes M, Brown MA, Franke A. Nat Genet. 2016 May;48(5):510-8. doi: 10.1038/ng.3528. Epub 2016 Mar 14.
  9. HLA Associations Distinguish Collagenous From Lymphocytic Colitis.
    Westerlind H, Bonfiglio F, Mellander MR, Hìbenthal M, Brynedal B, Björk J, Törkvist L, Padyukov L, Ohlsson B, Löfberg R, Hultcrantz R, Franke A, Bresso F, D’Amato M. Am J Gastroenterol. 2016 Aug;111(8):1211-3. doi: 10.1038/ajg.2016.215. No abstract available.
  10. Microscopic colitis: a descriptive clinical cohort study of 795 patients with collagenous and lymphocytic colitis. Mellander MR, Ekbom A, Hultcrantz R, Löfberg R, Öst Å, Björk J. Scand J Gastroenterol. 2016;51(5):556-62. doi: 10.3109/00365521.2015.112428
  11. Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea.Wagner M, Sjöberg K, Vigren L, Olesen M, Benoni C, Toth E, Carlson M. Scand J Gastroenterol. 2016 Jul;51(7):835-41. doi: 10.3109/00365521.2016.1141432.
  12. Smoking Status Influences Clinical Outcome in Collagenous Colitis. Münch A, Tysk C, Bohr J, Madisch A, Bonderup OK, Mohrbacher R, Mueller R, Greinwald R, Ström M, Miehlke S. J Crohns Colitis. 2016 Apr;10(4):449-54. doi: 10.1093/ecco-jcc/jjv235.PMID:26721941
  13. Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn’s Disease. Amcoff K, Joossens M, Pierik MJ, Jonkers D, Bohr J, Joossens S, Romberg-Camps M, Nyhlin N, Wickbom A, Rutgeerts PJ, Tysk C, Bodin L, Colombel JF, Vermeire S, Halfvarson J. J Crohns Colitis. 2016 Jun;10(6):695-702. doi: 10.1093/ecco-jcc/jjw021
  14. Zhulina Y, Udumyan R, Tysk C, Montgomery S, Halfvarson J. The changing face of Crohn’s disease: a population-based study of the natural history of Crohn’s disease in Örebro, Sweden 1963-2005. Scand J Gastroenterol. 2016 Mar;51(3):304-13.
  15. Development of an index to define overall disease severity in IBD. Siegel CA, Whitman CB, Spiegel BM, Feagan B, Sands B, Loftus EV Jr, Panaccione R, D’Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O’Morain C, Lakatos PL, McGovern DP, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. Gut. 2016 Oct 25. pii: gutjnl-2016-312648. doi: 10.1136/gutjnl-2016-312648.
  16. Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study. Oxelmark L, Lindberg A, Löfberg R, Sternby B, Eriksson A, Almer S, Befrits R, Fossum B, Karlén P, Broström O, Tysk C; SOIBD, the Swedish Organization for the study of Inflammatory Bowel Disease.Eur J Gastroenterol Hepatol. 2016 Nov;28(11):1320-8. doi: 10.1097/MEG.0000000000000710.
  17. Nordenvall C, Olén O, Nilsson PJ, Ekbom A, Bottai M, Myrelid P. The fate of reconstructive surgery following colectomy for inflammatory bowel disease in Sweden: A population-based cohort study. Journal of Crohn’s and Colitis 2016, accepted 29 February.
  18. Khalili H, Granath F, Smedby KE, Ekbom A, Neovius M, Chan AT, Olén O. Association Between Long-term Oral Contraceptive Use and Risk of Crohn’s Disease Complications in a Nationwide Study. Gastroenterology 2016;150:1561–1567.
  19. Khalili, Eriksson, Neovius, Ekbom, Ludvigsson, Askling, Chan, Olén. Oral Contraceptive Use and Risk of Ulcerative Colitis Progression: A Nationwide Study. American Journal of Gastroenterology 2016, accepted Aug 30.
  20. Ludvigsson JF, Büsch K, Olén O, Askling J, Smedby KE, Ekbom A, Lindberg E, Neovius M. Prevalence of Paediatric Inflammatory Bowel Disease in Sweden: a Nationwide Population-Based Register Study. BMC Gastroenterology, conditionally accepted 23 June 2016.
  21. Jakobsson GL, Sternegård E, Olén O, Myrelid P, Ljung R, Strid H, Halfvarson J, Ludvigsson JF. Validating inflammatory bowel disease in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG). Scandinavian Journal of Gastroenterology, accepted 5 October 2016.